金斯瑞生物科技(01548.HK)擬約17億港元購買合共3億股Probio Cayman A類優先股
格隆匯4月28日丨金斯瑞生物科技(01548.HK)發佈公告，於2025年4月28日，轉讓人、受讓人（公司直接全資附屬公司）及公司訂立股份轉讓協議，據此受讓人同意向轉讓人購買且轉讓人同意向受讓人出售合共3億股Probio Cayman A類優先股，於交割時總代價約爲2.25億美元（相當於約17億港元）。
於本公告日期，不考慮僱員持股計劃股份的未來配發及發行，公司直接及透過其直接全資附屬公司Probio BVI間接擁有Probio Cayman約71.72%。於交割時，不考慮僱員持股計劃股份的未來配發及發行，公司直接及透過其直接全資附屬公司Probio BVI及受讓人間接擁有Probio Cayman的權益將增加至85.09%。於交割時，Probio Cayman 將繼續爲公司的間接非全資附屬公司。
Probio Cayman及其附屬公司爲生物科技及製藥公司提供全面的合約開發及生產組織（CDMO）服務，涵蓋抗體藥物發現及臨牀前開發、生物製劑及治療用質粒和病毒的臨牀及商業生產。
憑藉集團在多個領域的深厚積澱，Probio Cayman已成長爲一家領先的CDMO服務提供商，爲抗體開發、蛋白療法、細胞療法及基因療法的創新者賦能。公司和蓬勃集團多年來一直投資於具有治療潛力的新分子實體、加速客戶的研發項目並保持 Probio Cayman 在技術創新領域的領先地位。此外，預計Probio Cayman會從與禮新醫藥科技有限公司就 PD-1 VHH抗體（該抗體後續用於PD-1 / VEGF 雙特異性抗體，並進一步許可給默沙東）達成的許可協議中獲得現金流入，因此，董事會對Probio Cayman未來的發展前景充滿信心。
鑑於Probio Cayman的業務潛力及其對集團的協同效益，董事會認爲轉讓爲集團提供機會以增加對Probio Cayman的持股及增強運營效率，從而爲公司帶來長期回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
